drugset / Trial / NCT05635162
Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma
RandomizedParallel-groupOpen-labelTreatment
Summary
Phase II, multicentre, randomised, open-label study to assess the benefit of early intervention with fixed duration, time-limited zanubrutinib-rituximab in indolent mantle cell lymphoma (MCL)
Timeline
- Start
- 2024-05-17
- Primary completion
- 2028-10
- Completion
- 2028-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Zanubrutinib | Small molecule | 160 mg | Oral |